# Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

> **NCT02103478** · PHASE1,PHASE2 · COMPLETED · sponsor: **Astex Pharmaceuticals, Inc.** · enrollment: 130 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- MDS

## Interventions

- **DRUG:** ASTX727 Dose Escalation
- **DRUG:** ASTX727 Dose Confirmation
- **DRUG:** ASTX727 Fixed-Dose Combination

## Key facts

- **NCT ID:** NCT02103478
- **Lead sponsor:** Astex Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-28
- **Primary completion:** 2018-06-05
- **Final completion:** 2019-12-04
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2024-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02103478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02103478, "Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02103478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*